Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
45.02 USD | -1.40% | +1.21% | +13.13% |
05-13 | Oppenheimer Adjusts Price Target on Soleno Therapeutics to $59 From $65, Maintains Outperform Rating | MT |
05-10 | Baird Starts Soleno Therapeutics With Outperform Rating, $72 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.13% | 1.66B | |
+8.59% | 114B | |
+10.80% | 104B | |
-12.90% | 22.41B | |
-1.19% | 22.28B | |
-5.24% | 19.07B | |
-38.29% | 18B | |
-5.05% | 17.89B | |
+7.57% | 14.28B | |
+35.84% | 12.55B |
- Stock Market
- Equities
- SLNO Stock
- News Soleno Therapeutics, Inc.
- Soleno Therapeutics Insider Sold Shares Worth $1,471,049, According to a Recent SEC Filing